Different effects of biological drugs in rheumatoid arthritis

…, M Benucci, S Sallì, S Bongiovanni, L Boccassini… - Autoimmunity …, 2013 - Elsevier
Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom
previously existing treatments could not control inflammation, joint destruction, or the …

Biomarkers in rheumatoid arthritis

…, IF Masala, S Bongiovanni, L Boccassini… - Israel Medical …, 2017 - air.unimi.it
Biomarkers are important for guiding the clinical and therapeutic management of all phases
of rheumatoid arthritis because they can help to predict disease development in subjects at …

Pain in fibromyalgia and related conditions

…, P Sarzi-Puttini, R Casale, M Cazzola, L Boccassini… - Reumatismo, 2014 - reumatismo.org
Pain is the hallmark symptom of fibromyalgia (FM) and other related syndromes, but quite
different from that of other rheumatic diseases, which depends on the degree of damage or …

[PDF][PDF] The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide

…, S Santandrea, L Boccassini… - Clinical and …, 2001 - clinexprheumatol.org
Methods Eighty patients entered a 4-week, doubl e-dum my, ra ndomised, cont ro lled stu dy.
Each patient was allocated to one of the following treatment groups: NIM 100 mg/day, NIM …

[PDF][PDF] New parameters for identifying subclinical atherosclerosis in patients with primary Sjögren's syndrome: a pilot study

…, L Gianturco, D Stella, L Boccassini… - Clin Exp …, 2014 - researchgate.net
… Fabiola Atzeni, MD, PhD Piercarlo Sarzi-Puttini, MD Maria Chiara Signorello, MD Luigi
Gianturco, MD Daniele Stella, MD Laura Boccassini, MD Cristian Ricci, PhD Bruno Dino Bodini …

Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis

…, L Gianturco, M Battellino, L Boccassini… - The Journal of …, 2011 - jrheum.org
… Plasma ADMA levels were significantly higher in the patients with PsA (0.71 ± 0.07 μmol/l vs
0.48 ± 0.07 μmol/l; p = 0.00) and CFR was significantly reduced in that group (2.86 ± 0.70 vs …

Anti-IL-17 agents in the treatment of axial spondyloarthritis

F Atzeni, A Carriero, L Boccassini… - ImmunoTargets and …, 2021 - Taylor & Francis
Axial spondyloarthritis (axSpA) describes a group of chronic inflammatory rheumatic diseases
primarily involving the axial skeleton. IL-17 is involved in the pathogenesis of numerous …

A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome

…, P Sarzi-Puttini, L Boccassini… - Journal of …, 1993 - journals.sagepub.com
In a double-blind crossover study, the efficacy and tolerability of oral cyclobenzaprine
administered in two different regimens were compared in 40 patients affected by primary …

Diet therapy for rheumatoid arthritis: A controlled double-blind study of two different dietary regimens

P Sarzi-Puttini, D Comi, L Boccassini… - Scandinavian journal …, 2000 - Taylor & Francis
Objective: To evaluate the effects of a diet therapy in patients with rheumatoid arthritis (RA).
Methods: Fifty RA patients entered a 24-week double-blind, randomised, controlled-study of …

Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome

I Caruso, PCS Puttini, L Boccassini… - Journal of …, 1987 - journals.sagepub.com
A double-blind study comparing the efficacy and tolerability of dothiepin with that of placebo
in the treatment of primary fibromyalgia syndrome was carried out. Dothiepin was shown to …